Nicotine/mecamylamine combination treatment for smoking cessation

Rose, Jed E.; Westman, Eric; Behm, Frédérique M.

doi:10.1002/(sici)1098-2299(199607/08)38:3/4<243::aid-ddr13>3.0.co;2-#

Cited by 32 publications

(11 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The marked reduction in smoking in the combined nicotine/mecamylamine treatment condition was corroborated by measurements of expired Fig. 3 Ad libitum smoking rates (mean ± SEM) from study described in Rose et al (1996). Data depict smoking behavior during 28 days of receiving nicotine alone (nic/no mec), mecamylamine alone (no nic/mec), nicotine+mecamyl-amine (nic/mec) or neither drug (no nic/no mec).…”

Section: Nicotine-mecamylamine Combination In Treatment Of Smokingmentioning

confidence: 64%

“…Rose and Levin (1991a) proposed that the problems of mecamylamine therapy could be solved by the use of lower doses and by combining the paradigms of nicotine substitution and nicotine blockade. In recent work, Rose et al (1996) have shown that concurrent administration of nicotine with mecamylamine produces greater suppression of ad libitum smoking behavior than either agent alone (see below). Although the value of a nicotine/mecamylamine combination may initially seem counterintuitive, nicotine and mecamylamine both "occupy" receptors that would otherwise be acted upon by nicotine from cigarettes [even though the two drugs bind to different sites in the receptor-ion channel complex (Martin et al 1989)].…”

Section: Nicotine-mecamylamine Combination In Treatment Of Smokingmentioning

confidence: 99%

“…In a recent follow-up study (Rose et al 1996), 80 subjects received 4 weeks of pre-cessation treatment with either: nicotine/mecamylamine (21 mg/24 h nicotine patch, 5 mg b.i.d. oral mecamylamine), nicotine alone, mecamylamine alone, or placebo.…”

Section: Nicotine-mecamylamine Combination In Treatment Of Smokingmentioning

confidence: 99%

See 2 more Smart Citations

Nicotine self-administration in animals and humans: similarities and differences

1997

View full text Add to dashboard Cite

Studies of nicotine self-administration in animal and human subjects are discussed with respect to the behavioral paradigms employed, the effects of nicotine dose manipulations and nicotinic agonist/antagonist pretreatment, and the role of neurochemical processes mediating reinforcement. Animal models have focused on intravenous nicotine self-administration, while most studies in human subjects have studied cigarette smoking behavior. Despite procedural differences, data from both animal and human studies show an inverted-U function relating nicotine dose to self-administration behavior, with maximal rates of responding occurring at intermediate doses of nicotine. Moreover, nicotine supplementation via non-contingent nicotine administration suppresses nicotine self-administration behavior in both animal models and human cigarette smokers. Nicotine antagonist treatment also reduces responding, although human studies usually find a transient increase in smoking, which is interpreted as an attempt to compensate for nicotinic receptor blockade. Amongst the neurochemical systems which have been examined, most emphasis has been given to dopamine. The mesolimbic dopamine pathway has been implicated in nicotine reward based on animal studies, and research with humans suggests a role for dopaminergic processes as well. However, dopaminergic blockade appears to increase cigarette smoking behavior in humans, while in animals nicotine self-administration is attenuated. Future research should exploit the complementary aspects of animal models and human paradigms to provide a coherent understanding of nicotine reinforcement. Animal models allow for analysis of anatomical and physiological mechanisms underlying nicotine self-administration; human studies validate the relevance to tobacco dependence and smoking cessation treatment.

show abstract

Section: Nicotine-mecamylamine Combination In Treatment Of Smokingmentioning

confidence: 64%

Section: Nicotine-mecamylamine Combination In Treatment Of Smokingmentioning

confidence: 99%

See 1 more Smart Citation

Nicotine self-administration in animals and humans: similarities and differences

1997

View full text Add to dashboard Cite

show abstract

“…It might be noted that for the nicotine field, in the area of smoking cessation, the combination of nicotine and mecamylamine has shown effectiveness in clinical trials. 21 The addition of the antagonist to the regimen was considered to inhibit the rewarding effects of smoking, thus promoting extinction of the behavior. The agonist was included to prevent nicotine withdrawal and craving.…”

Section: Attenuation Of Peripheral Side Effectsmentioning

confidence: 99%

Multifunctional Receptor-Directed Drugs for Disorders of the Central Nervous System

Buccafusco

2009

Neurotherapeutics

View full text Add to dashboard Cite

“…[88][89][90] Consequently, therapeutic use has been discontinued, except in cases of severe hypertension, in favour of more specific antihypertensives affecting only the sympathetic nervous system. 91 This lower dosage avoids or minimises the severity of side effects, allowing for mecamylamine to potentially be used to treat conditions, such as addiction and depression (e.g. 91 This lower dosage avoids or minimises the severity of side effects, allowing for mecamylamine to potentially be used to treat conditions, such as addiction and depression (e.g.…”

Section: Mecamylaminementioning

confidence: 99%

Pharmaceuticals that contain polycyclic hydrocarbon scaffolds

2015

View full text Add to dashboard Cite

Numerous variations on structural motifs exist within pharmaceutical compounds that have entered the clinic. These variations have amounted over many decades based on years of drug development associated with screening natural products and de novo synthetic systems. Caged (or bridged) bicyclic structural elements offer a variety of diverse features, encompassing three-dimensional shape, and assorted pharmacokinetic properties. This review highlights approximately 20 all carbon cage containing pharmaceuticals, ranging in structure from bicyclo[2.2.1] through to adamantane, including some in the top-selling pharmaceutical bracket. Although, a wide variety of human diseases, illnesses and conditions are treated with drugs containing the bicyclic motif, a common feature is that many of these lipophilic systems display CNS and/or neurological activity. In addition, to an extensive overview of the history and biology associated with each drug, a survey of synthetic methods used to construct these entities is presented. An analysis section compares natural products to synthetics in drug discovery, and entertains the classical caged hydrocarbon systems potentially missing from the clinic. Lastly, this unprecedented review is highly pertinent at a time when big pharma is desperately trying to escape flatland drugs.

show abstract

Nicotine/mecamylamine combination treatment for smoking cessation

Cited by 32 publications

References 49 publications

Nicotine self-administration in animals and humans: similarities and differences

Nicotine self-administration in animals and humans: similarities and differences

Multifunctional Receptor-Directed Drugs for Disorders of the Central Nervous System

Pharmaceuticals that contain polycyclic hydrocarbon scaffolds

Contact Info

Product

Resources

About